1 completed, 1 recruiting, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Sorafenib: new trials by email Literature Review of Sorafenib trials Research Report on Sorafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib Gilteritinib, Sorafenib - Acute Myeloid Leukemia (AML), FLT3-ITD Mutation | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 594 | 2026-05-01 | 2026-03-20 |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT Radiotherapy plus Toripalimab, Sorafenib - Radiotherapy, Toripalimab | Phase 3 | Terminated | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 36 | 2021-03-02 | 2025-02-26 |
| TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma TACE+sorafenib, TACE - Hepatocellular Carcinoma, Sorafenib | Phase 3 | Completed | Sun Yat-sen University | 162 | 2019-10-02 | 2024-02-28 |
Carcinoma, Hepatocellular (1) · Leukemia, Myeloid, Acute (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Adenocarcinoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Liver Diseases (1) · Liver Neoplasms (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1)
Sorafenib (2) · Radiotherapy (1) · gilteritinib (1) · toripalimab (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Soochow University (1)
China (3)
Ming Kuang, PhD (1)